Myotonic Dystrophy Pipeline

(Las Vegas, Nevada, United States) “Myotonic Dystrophy Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myotonic Dystrophy Market.

The Myotonic Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Click here to know more about the Myotonic Dystrophy drugs in different phases of development –  Myotonic Dystrophy Pipeline Analysis

Some of the key takeaways from the Myotonic Dystrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myotonic Dystrophy treatment therapies with a considerable amount of success over the years. 
• Myotonic Dystrophy companies working in the treatment market are  Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana, Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others, are developing therapies for the Myotonic Dystrophy treatment 

• Emerging Myotonic Dystrophy therapies such as – Mexiletine, Tideglusib, Pitolisant, AOC 1001, DYNE-101, NXEN04, Research programme: neuromuscular gene therapies, ENTR-701, ATX-01, NT-0200, NT 0231 F, ENZ-001, ENZ003, AT 466, Dyne-102, PGN EDODM1, Research Programme: Type1 Muscular Dystrophy, Research programme: myotonic dystrophy therapeutics, and others are expected to have a significant impact on the Myotonic Dystrophy market in the coming years.
• In March 2021, AlloVir initiated a Phase III study to evaluate ALVR105 (Viralym-M); an In August 2022, the US granted Arthex Biotech’s lead investigational product ATX-01 Orphan Drug Designation (ODD). Food and Drug Administration (FDA). ATX-01 is under development for the treatment of Myotonic Dystrophy Type 1 (DM1), a serious, debilitating, and life-threatening disease with no known cure or currently available drug treatment.
• In July 2022, Dyne Therapeutics, Inc. announced that the New Zealand Medicines and Medical Devices Safety Authority cleared its clinical trial application to initiate its Phase I/II multiple ascending doses (MAD) clinical trials of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). 

Myotonic Dystrophy Overview

Myotonic Dystrophy (DM) is considered a subgroup of myopathy and the most common type of muscular dystrophy that begins in adulthood. There are two major forms recognized based on clinical and molecular presentation: Myotonic dystrophy type I (DM1), known as Steinert disease, and myotonic dystrophy type II (DM2), or proximal myotonic myopathy which is a milder variety of DMI. These are progressive, multisystem genetic disorders.

Get a Free Sample PDF Report to know more about Myotonic Dystrophy Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight

Emerging Myotonic Dystrophy Drugs Under Different Phases of Clinical Development Include:

• Mexiletine: Lupin
• AMO-02: AMO Pharma
• Pitolisant: Harmony Biosciences
• AOC 1001: Avidity Biosciences
• DYNE-101: Dyne Therapeutics
• ENTR-701: Entrada Therapeutics 

Route of Administration

Myotonic Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Myotonic Dystrophy Pipeline Therapeutics Assessment

• Myotonic Dystrophy Assessment by Product Type
• Myotonic Dystrophy By Stage and Product Type
• Myotonic Dystrophy Assessment by Route of Administration
• Myotonic Dystrophy By Stage and Route of Administration
• Myotonic Dystrophy Assessment by Molecule Type
• Myotonic Dystrophy by Stage and Molecule Type

DelveInsight’s Myotonic Dystrophy Report covers around 28+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myotonic Dystrophy product details are provided in the report. Download the Myotonic Dystrophy pipeline report to learn more about the emerging Myotonic Dystrophy therapies – – https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight

Myotonic Dystrophy Pipeline Analysis:

The Myotonic Dystrophy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Myotonic Dystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myotonic Dystrophy Treatment.
• Myotonic Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myotonic Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myotonic Dystrophy market.

Download Sample PDF Report to know more about Myotonic Dystrophy drugs and therapies- https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight

Scope of Myotonic Dystrophy Pipeline Drug Insight    

• Coverage: Global
• Key Myotonic Dystrophy Companies: Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana, Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others
• Key Myotonic Dystrophy Therapies: Mexiletine, Tideglusib, Pitolisant, AOC 1001, DYNE-101, NXEN04, Research programme: neuromuscular gene therapies, ENTR-701, ATX-01, NT-0200, NT 0231 F, ENZ-001, ENZ003, AT 466, Dyne-102, PGN EDODM1, Research Programme: Type1 Muscular Dystrophy, Research programme: myotonic dystrophy therapeutics, and others
• Myotonic Dystrophy Therapeutic Assessment: Myotonic Dystrophy current marketed and Myotonic Dystrophy emerging therapies
• Myotonic Dystrophy Market Dynamics: Myotonic Dystrophy market drivers and Myotonic Dystrophy market barriers 

Request for Sample PDF Report for Myotonic Dystrophy Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting